Raglan established a second orphan focused company in mid-2017 called Open Orphan, following on from the success of its first rare disease pharma company, Amryt Pharma plc. Open Orphan plc is a building a leading European rare/orphan focused pharma services company. Open Orphan is led by an experienced Board and management team with expertise in orphan drug regulatory approval, market access and reimbursement, commercialisation and launch optimisation. Open Orphan completed its IPO in June 2019 via the reverse takeover of Venn Life Sciences and is now listed on the London AIM stock exchange and the Euronext growth exchange.

In 2016, Raglan established Amryt Pharma Plc which is also listed on both the London and Euronext Stock Exchanges and soon to be listing on the NASDAQ exchange. Following Amryt’s recent acquisition of Aegerion Pharmaceuticals in September 2019, it has a market capitalisation in excess of £190m and is now an established European and North America orphan drug company. The company already has rapidly growing monthly sales revenues while at the same time managing a pipeline of drugs in development including its potential blockbuster EB orphan drug, which is now in its final FDA phase three trials.

Raglan has also been very active in the Oil & Gas sector for many years and as such, we hold in-depth knowledge of the industry having completed a variety of related projects. T5 Oil & Gas, which is another in-house Raglan creation, is due to complete its IPO mid-2018. Prior to that, Raglan established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m.

The team behind Raglan Capital have many years of deal making experience with a proven track record of achieving exceptional results.

With offices in Dublin, London and Vienna, our relationships include regular contact with the Dublin and international stock brokers, investment banks, private equity firms and a broad range of investors which provides Raglan Capital with invaluable access to local advisers and contacts when completing international transactions.